Skip to main content
INOVIQ LTD logo

INOVIQ LTD — Investor Relations & Filings

Ticker · IIQ ISIN · AU0000196149 ASX Professional, scientific and technical activities
Open in API
Filings indexed 858 across all filing types
Latest filing 2017-06-27 Management Reports
Country AU Australia
Listing ASX IIQ

About INOVIQ LTD

https://www.inoviq.com

INOVIQ LTD specializes in the development and commercialization of next-generation exosome and precision diagnostics. The company focuses on innovative solutions for the early detection and monitoring of cancer and other diseases. Its proprietary technology portfolio includes EXO-NET, a high-throughput exosome capture tool designed for research and clinical applications, and the SubB2M platform, which utilizes an engineered protein to detect the pan-cancer biomarker Neu5Gc. The company also provides the hTERT test for bladder cancer monitoring. These technologies facilitate non-invasive liquid biopsy tests aimed at improving patient outcomes through high sensitivity and specificity. The core business activities encompass the creation of diagnostic tools and research reagents for the global healthcare and life sciences sectors, emphasizing precision medicine and early intervention.

Recent filings

Filing Released Lang Actions
Shareholder Update 5 pages 305.4KB
Management Reports Classification · 95% confidence The document is a detailed shareholder update from BARD1 Life Sciences Limited, dated 28 June 2017. It provides comprehensive information on the company's business strategy, research and development programs, diagnostic test performance data, and financial update including cash balance. The content includes detailed scientific and clinical study results, development plans, and financial status, which are typical of a management report or shareholder update rather than a brief announcement or regulatory filing. The document is lengthy (15,000 characters) and contains substantive data and analysis, not just a summary or announcement. It is not an earnings release, annual report, or interim report as it lacks formal financial statements and comprehensive fiscal year coverage. It is not a call transcript, audit report, or legal proceeding update. The document focuses on management's explanation of business progress, R&D updates, and outlook, fitting the Management Reports (MDA) category best.
2017-06-27 English
Lung Cancer Study Results 2 pages 215.4KB
Regulatory Filings Classification · 95% confidence The document is an announcement of study results for a lung cancer test by BARD1 Life Sciences Limited. It provides details about the research study, statistical analysis, and future plans for assay development and clinical validation. The content is a press release style update on research progress and does not contain financial statements, regulatory filings, or detailed investor presentations. It is not an annual or interim report, earnings release, or any formal regulatory filing. It is a scientific and product development update, which fits best under the category of a general regulatory announcement or miscellaneous company update. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2017-05-14 English
Quarterly Activities Report and Appendix 4C 8 pages 834.5KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'QUARTERLY BUSINESS UPDATE' and provides detailed financial and operational information for the third quarter ending 31 March 2017. It includes a financial update with cash flow statements, R&D updates, patent information, and a detailed Appendix 4C quarterly report, which is a standard Australian Securities Exchange (ASX) quarterly cash flow report. The document contains substantive financial data and analysis for a period shorter than a full fiscal year, consistent with an interim or quarterly report. It is not merely an announcement or a brief summary but a comprehensive quarterly report with financial statements and operational commentary. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q3 2017
2017-04-27 English
Shareholder Update 2 pages 216.0KB
Regulatory Filings Classification · 90% confidence The document is a shareholder update from BARD1 Life Sciences Limited regarding the status of its lung cancer diagnostics program. It provides detailed information about the ongoing study, preliminary results, and future expectations for reporting. The content is focused on operational progress and research updates rather than financial results or regulatory filings. It is not an annual or interim financial report, audit report, earnings release, or any other formal regulatory filing. The document is a communication to shareholders providing an update on a specific project, which fits the category of a shareholder update. Given the definitions, this type of document aligns best with Regulatory Filings (RNS) as a general regulatory announcement or miscellaneous filing that does not fit other categories.
2017-04-17 English
Cancer Vaccine Collaboration 2 pages 230.4KB
Regulatory Filings Classification · 95% confidence The document is a press release announcing a new research collaboration between BARD1 Life Sciences Limited and the Institute for Respiratory Health to evaluate a cancer vaccine. It discusses the project scope, potential market size, and company background. There are no financial statements, regulatory filings, or detailed financial data presented. The content is primarily an announcement of a collaboration and research initiative rather than a financial report, management discussion, or regulatory filing. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or any other financial or regulatory report types. The document is best classified as a general Regulatory Filing (RNS) because it is a corporate announcement that does not fit other specific categories.
2017-04-04 English
Appendix 3B 12 pages 760.8KB
Capital/Financing Update Classification · 100% confidence The document is titled 'Appendix 3B New issue announcement' and contains detailed information about the issuance of new securities, including the class and number of securities issued, terms, escrow details, issue price, purpose of the issue, and compliance with ASX rules. It also includes calculations related to placement capacity under ASX Listing Rules 7.1 and 7.1A, which govern the issuance of new shares and capital raising activities. The document is a formal announcement to the ASX regarding a new share issue and application for quotation of additional securities. It is not a financial report, earnings release, or management discussion, but rather a regulatory announcement about capital raising and share issuance. Therefore, the appropriate classification is 'Capital/Financing Update' (CAP). The document length (15,000 characters) and content confirm it is a full announcement, not just a brief notice or report publication announcement.
2017-03-28 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.